FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W366249503> ?p ?o ?g. }

• W366249503 endingPage "52" @default.
• W366249503 startingPage "44" @default.
• W366249503 abstract "Neuroblastoma is a childhood cancer with poor long-term prognosis in advanced stages. A major aim in neuroblastoma therapy is to develop targeted drug delivery systems to ameliorate drug therapeutic index and efficacy. In this study, a novel bortezomib (BTZ) liposomal formulation was set-up and characterized. Since BTZ is freely permeable across the lipidic bilayer, an amino-lactose (LM) was synthesized as complexing agent to entrap BTZ inside the internal aqueous compartment of stealth liposomes. High encapsulation efficiency was achieved by a loading method based on the formation of boronic esters between the boronic acid moiety of BTZ and the hydroxyl groups of LM. Next, NGR peptides were linked to the liposome surface as a targeting-ligand for the tumor endothelial cell marker, aminopeptidase N. Liposomes were characterized for size, Z-potential, polydispersity index, drug content, and release. Lyophilization in the presence of cryoprotectants (trehalose, sucrose) was also examined in terms of particle size changes and drug leakage. BTZ was successfully loaded into non-targeted (SL[LM-BTZ]) and targeted (NGR-SL[LM-BTZ]) liposomes with an entrapment efficiency of about 68% and 57%, respectively. These nanoparticles were suitable for intravenous administration, presenting an average diameter of 170nm and narrow polydispersity. Therefore, orthotopic NB-bearing mice were treated with 1.0 or 1.5mg/kg of BTZ, either in free form or encapsulated into liposomes. BTZ loaded liposomes showed a significant reduction of drug systemic adverse effects with respect to free drug, even at the highest dose tested. Moreover, mice treated with 1.5mg/kg of NGR-SL[LM-BTZ] lived statistically longer than untreated mice (P=0.0018) and SL[LM-BTZ]-treated mice (P=0.0256). Our results demonstrate that the novel vascular targeted BTZ formulation is endowed with high therapeutic index and low toxicity, providing a new tool for future applications in neuroblastoma clinical studies." @default.
• W366249503 created "2016-06-24" @default.
• W366249503 creator A5000217335 @default.
• W366249503 creator A5000242295 @default.
• W366249503 creator A5008442547 @default.
• W366249503 creator A5008463036 @default.
• W366249503 creator A5015444918 @default.
• W366249503 creator A5023513144 @default.
• W366249503 creator A5027704478 @default.
• W366249503 creator A5035931487 @default.
• W366249503 creator A5042376678 @default.
• W366249503 creator A5047134412 @default.
• W366249503 creator A5050938468 @default.
• W366249503 creator A5053922930 @default.
• W366249503 creator A5062757807 @default.
• W366249503 creator A5070686436 @default.
• W366249503 creator A5079474442 @default.
• W366249503 creator A5082141553 @default.
• W366249503 creator A5083711626 @default.
• W366249503 creator A5088779262 @default.
• W366249503 date "2015-08-01" @default.
• W366249503 modified "2023-10-15" @default.
• W366249503 title "Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma" @default.
• W366249503 cites W1690464810 @default.
• W366249503 cites W1762081208 @default.
• W366249503 cites W1977303037 @default.
• W366249503 cites W1978735501 @default.
• W366249503 cites W1995986211 @default.
• W366249503 cites W1996275708 @default.
• W366249503 cites W2000016139 @default.
• W366249503 cites W2009426416 @default.
• W366249503 cites W2014562478 @default.
• W366249503 cites W2027828682 @default.
• W366249503 cites W2033494194 @default.
• W366249503 cites W2039374629 @default.
• W366249503 cites W2041759339 @default.
• W366249503 cites W2043009231 @default.
• W366249503 cites W2046542140 @default.
• W366249503 cites W2053650083 @default.
• W366249503 cites W2058879480 @default.
• W366249503 cites W2067653691 @default.
• W366249503 cites W2075771522 @default.
• W366249503 cites W2076226743 @default.
• W366249503 cites W2076800875 @default.
• W366249503 cites W2082978870 @default.
• W366249503 cites W2088190878 @default.
• W366249503 cites W2092636163 @default.
• W366249503 cites W2093353574 @default.
• W366249503 cites W2095296988 @default.
• W366249503 cites W2096552337 @default.
• W366249503 cites W2096593771 @default.
• W366249503 cites W2100940126 @default.
• W366249503 cites W2103184797 @default.
• W366249503 cites W2103872295 @default.
• W366249503 cites W2108522140 @default.
• W366249503 cites W2110788947 @default.
• W366249503 cites W2117697469 @default.
• W366249503 cites W2122937570 @default.
• W366249503 cites W2130465135 @default.
• W366249503 cites W2158221216 @default.
• W366249503 cites W2160591216 @default.
• W366249503 cites W2162449950 @default.
• W366249503 cites W2164202115 @default.
• W366249503 cites W2168093560 @default.
• W366249503 cites W2168980644 @default.
• W366249503 doi "https://doi.org/10.1016/j.jconrel.2015.05.286" @default.
• W366249503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26031842" @default.
• W366249503 hasPublicationYear "2015" @default.
• W366249503 type Work @default.
• W366249503 sameAs 366249503 @default.
• W366249503 citedByCount "48" @default.
• W366249503 countsByYear W3662495032016 @default.
• W366249503 countsByYear W3662495032017 @default.
• W366249503 countsByYear W3662495032018 @default.
• W366249503 countsByYear W3662495032019 @default.
• W366249503 countsByYear W3662495032020 @default.
• W366249503 countsByYear W3662495032021 @default.
• W366249503 countsByYear W3662495032022 @default.
• W366249503 countsByYear W3662495032023 @default.
• W366249503 crossrefType "journal-article" @default.
• W366249503 hasAuthorship W366249503A5000217335 @default.
• W366249503 hasAuthorship W366249503A5000242295 @default.
• W366249503 hasAuthorship W366249503A5008442547 @default.
• W366249503 hasAuthorship W366249503A5008463036 @default.
• W366249503 hasAuthorship W366249503A5015444918 @default.
• W366249503 hasAuthorship W366249503A5023513144 @default.
• W366249503 hasAuthorship W366249503A5027704478 @default.
• W366249503 hasAuthorship W366249503A5035931487 @default.
• W366249503 hasAuthorship W366249503A5042376678 @default.
• W366249503 hasAuthorship W366249503A5047134412 @default.
• W366249503 hasAuthorship W366249503A5050938468 @default.
• W366249503 hasAuthorship W366249503A5053922930 @default.
• W366249503 hasAuthorship W366249503A5062757807 @default.
• W366249503 hasAuthorship W366249503A5070686436 @default.
• W366249503 hasAuthorship W366249503A5079474442 @default.
• W366249503 hasAuthorship W366249503A5082141553 @default.
• W366249503 hasAuthorship W366249503A5083711626 @default.
• W366249503 hasAuthorship W366249503A5088779262 @default.

• next